Pure Global
NCT06403631

Supporting Mental Health in Daily Life After the Diagnosis of Multiple Sclerosis

Supporting Mental Health in Daily Life After the Diagnosis of Multiple Sclerosis: the Role of Flow Experience and Mindfulness
Marta Bassi·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Multiple Sclerosis
Drug/Device/Intervention
observational
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Marta Bassi
Funder
University of Milan
Location
Bari,Cagliari,Catania,Como,Florence,Milano,Orbassano,Roma, Italy
Timeline & enrollment
Phase
N/A
Start date
Nov 06, 2023
End date
Feb 28, 2026
Enrollment
123 participants
Primary outcome

Positive mental health (Mental Health Continuum Short Form),Anxiety (subscale of the Hospital Anxiety and Depression Scale),Depression (subscale of the Hospital Anxiety and Depression Scale)

Summary

The overall goal of this observational study is to learn about the psychological resources of
 mindfulness and flow experience available to persons newly diagnosed with multiple sclerosis
 (MS). The primary study aim will be to analyze the relation of flow and mindfulness with
 mental health among individuals who received an MS diagnosis within the last year. Secondary
 aims will be to analyze the daily activities preferentially associated with flow, and to
 evaluate possible changes in daily flow retrieval. Participants will answer questionnaires
 measuring flow, mindfulness, positive mental health, anxiety and depression at project start
 and 6 months later.

ICD-10 classifications
Multiple sclerosisProgressive systemic sclerosisSystemic sclerosisSystemic sclerosis, unspecifiedDiffuse sclerosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06403631
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06403631 through Pure Global AI's free database. This phase not specified trial is sponsored by Marta Bassi and is currently Recruiting. The study focuses on Multiple Sclerosis. Target enrollment is 123 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.